Eli Lilly Enters Psychedelic Mental Health Space with $3.8 Billion AtaiBeckley Acquisition
Eli Lilly secures BPL-003 and other novel psychedelic-inspired treatments designed to provide rapid, long-lasting relief for treatment-resistant depression.
/ 9 items
#ATAI↓
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
Social Anxiety Breakthrough or Overhyped Experiment? AtaiBeckley's R-MDMA Divides Opinion
AtaiBeckley (ATAI) tested an R-MDMA pill for social anxiety. Results looked promising — but the trial was tiny, just 6 weeks, and far from FDA approval.
JonesResearch Starts Coverage on Atai Beckley & Mind Medicine with Buy Ratings
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.